Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

The Use of Functional Confections in Promoting Oral Health

NCT01514552
View directory record Official record
Conditions
Oral Health, Oral Cancer, Gum Disease
Interventions
Strawberry gummy, Placebo control gummy
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 29, 2026, 3:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Electromyography in Labor and Parturition

NCT03899493
View directory record Official record
Conditions
Labor
Interventions
Observation
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Not applicable Interventional Results available

Optimizing Functional Recovery of Breast Cancer Survivors

NCT03915548
View directory record Official record
Conditions
Breast Cancer Female
Interventions
The Behavioral Activation/ Problem Solving Intervention, Attention Control Condition
Behavioral
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
18 Years and older · Female only
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential

NCT02706535
View directory record Official record
Conditions
Drug Interactions, Neoplasms
Interventions
GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Women Exercising, Active, and Learning Together 2.0

NCT06785025
View directory record Official record
Conditions
Stress, Depression Secondary to Other Disease, Anxiety, Physical Activity
Interventions
Group-Based Dance Fitness Intervention
Behavioral
Lead sponsor
Louisiana State University and A&M College
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 29, 2026, 3:09 PM EDT
Active, not recruiting Phase 2 Interventional Results available

RANKL Inhibition and Mammographic Breast Density

NCT04067726
View directory record Official record
Conditions
Dense Breasts
Interventions
Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 29, 2026, 3:09 PM EDT
Terminated Phase 3 Interventional Results available

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

NCT01237340
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
Saizen®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
US Medical Information, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 29, 2026, 3:09 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)

NCT01389817
View directory record Official record
Conditions
Leber's Hereditary Optic Neuropathy (LHON)
Interventions
Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 3 Interventional

Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer

NCT00003855
View directory record Official record
Conditions
Breast Cancer
Interventions
axillary lymph node dissection, whole breast irradiation
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PREVENT Pilot HPV - Related Cancers Trial

NCT06738355
View directory record Official record
Conditions
HPV Vaccination, Uptake Vaccination, Series Completion
Interventions
PREVENT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 29, 2026, 3:09 PM EDT
Not listed Phase 2 Interventional

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

NCT00027989
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Pharmatech Oncology
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
6
States / cities
Montgomery, Alabama • West Covina, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

NCT02530710
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Q203, Placebo
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Start the Conversation: Evaluating Implementation of a Multi-level PrEP Initiative for Black Cisgender Women in Nola

NCT05909176
View directory record Official record
Conditions
Preexposure Prophylaxis, HIV Infections
Interventions
GYN Residency Training, Social Media Campaign
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 99 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Oral Remimazolam With and Without Alcohol in Healthy Female Subjects

NCT04113343
View directory record Official record
Conditions
Safety Issues
Interventions
Remimazolam, Alcohol
Drug · Other
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
21 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea

NCT02210325
View directory record Official record
Conditions
Uncomplicated Urogenital Gonorrhea
Interventions
solithromycin, ceftriaxone, azithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

NCT05579574
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 29, 2026, 3:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT05086315
View directory record Official record
Conditions
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Interventions
SAR443579
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers

NCT00449774
View directory record Official record
Conditions
Mental Disorders
Interventions
Lamotrigine IR tablets, Lamotrigine ODT tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 29, 2026, 3:09 PM EDT
Recruiting Not applicable Interventional

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120
View directory record Official record
Conditions
Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Interventions
Single arterial graft, Multiple arterial grafting
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
42
States / cities
Los Angeles, California • Pomona, California • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 29, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional Results available

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

NCT02000596
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women

NCT02092571
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Progesterone vaginal ring,
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne

NCT06936332
View directory record Official record
Conditions
Acne
Interventions
Omnilux Clear Light Emitting Diode Treatment
Device
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

NCT06476834
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deucravacitinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 29, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants

NCT03589768
View directory record Official record
Conditions
Clostridium Difficile Immunisation, Diphtheria, Diphtheria Immunisation, Pertussis, Tetanus, Tetanus Immunisation
Interventions
Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 29, 2026, 3:09 PM EDT